The estimated Net Worth of Matthew P. Young is at least $8.89 Milion dollars as of 5 March 2019. Mr. Young owns over 1,152 units of PRA Health Sciences Inc stock worth over $5,980,602 and over the last 11 years he sold PRAH stock worth over $2,696,209. In addition, he makes $210,000 as Independent Director at PRA Health Sciences Inc.
Sign up
Mr. Young PRAH stock SEC Form 4 insiders trading
Matthew has made over 16 trades of the PRA Health Sciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,152 units of PRAH stock worth $155,992 on 5 March 2019.
The largest trade he's ever made was selling 5,115 units of PRA Health Sciences Inc stock on 16 November 2017 worth over $408,689. On average, Matthew trades about 494 units every 9 days since 2014. As of 5 March 2019 he still owns at least 36,200 units of PRA Health Sciences Inc stock.
You can see the complete history of Mr. Young stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Young biography
Matthew P. Young serves as Independent Director of the Company. Mr. Young has served as Chief Operating Officer and Chief Financial Officer of GRAIL, Inc., a biotechnology company, since October 2019. Mr. Young previously served as Chief Financial Officer of Jazz Pharmaceuticals plc, a biopharmaceutical company, from March 2014 to October 2019. Prior to his appointment as Chief Financial Officer of Jazz Pharmaceuticals, he served as Senior Vice President, Corporate Development beginning in April 2013. He also has served on the board of directors and nominating and corporate governance committee, as well as chairman of the audit committee, of CytomX Therapeutics since November 2015. Prior to joining Jazz Pharmaceuticals, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, Mr. Young served as a managing director in global healthcare of Barclays Capital Inc., where his role included acting as the co-head of life sciences. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., and from 2003 to 2007 he served as a managing director of Lehman Brothers Inc. From 1992 to 2003, Mr. Young served in various capacities at other investment banking firms. Mr. Young received a B.S. in Economics and an M.B.A. from the Wharton School of the University of Pennsylvania.
What is the salary of Matthew Young?
As the Independent Director of PRA Health Sciences Inc, the total compensation of Matthew Young at PRA Health Sciences Inc is $210,000. There are 5 executives at PRA Health Sciences Inc getting paid more, with Colin Shannon having the highest compensation of $7,160,220.
How old is Matthew Young?
Matthew Young is 50, he's been the Independent Director of PRA Health Sciences Inc since 2015. There are 7 older and 2 younger executives at PRA Health Sciences Inc. The oldest executive at PRA Health Sciences Inc is Jeffrey Barber, 67, who is the Independent Director.
What's Matthew Young's mailing address?
Matthew's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at PRA Health Sciences Inc
Over the last 10 years, insiders at PRA Health Sciences Inc have traded over $5,843,308,181 worth of PRA Health Sciences Inc stock. The most active insiders traders include Fund Holdings L.P.Kkr Fund ..., Fund Holdings L.P.Kkr Fund ... oraz Pra Investors L.P.Kkr Pra I.... On average, PRA Health Sciences Inc executives and independent directors trade stock every 39 days with the average trade being worth of $280,602,577. The most recent stock trade was executed by Christopher L Gaenzle on 17 June 2021, trading 27,497 units of PRAH stock currently worth $2,773,897.
What does PRA Health Sciences Inc do?
PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.
What does PRA Health Sciences Inc's logo look like?
Complete history of Mr. Young stock trades at CytomX Therapeutics Inc, Jazz Pharmaceuticals plc oraz PRA Health Sciences Inc
PRA Health Sciences Inc executives and stock owners
PRA Health Sciences Inc executives and other stock owners filed with the SEC include:
-
Colin Shannon,
Chairman of the Board, President, Chief Executive Officer -
Michael Bonello,
Chief Financial Officer, Executive Vice President -
Colin Shannon,
Chairman, CEO & Pres -
Linda Grais,
Independent Director -
Jeffrey Barber,
Independent Director -
Matthew Young,
Independent Director -
Alexander Dickinson,
Independent Director -
James Momtazee,
Lead Independent Director -
Glen Stettin,
Independent Director -
Christopher Gaenzle,
Executive Vice President, Chief Administrative Officer, General Counsel -
Dr. Michael Kirchengast,
Sr. VP of Scientific Affairs -
Patrick R. Spine,
VP of HR -
Tami Klerr-Naivar,
Exec. VP and Chief Sales & Marketing Officer -
Laurie Hurst,
Sr. Director of Communications & PR -
Thomas Byrne,
VP of Legal Affairs -
Kent Thoelke,
Exec. VP & Chief Scientific Officer -
Margaret Keegan,
Exec. VP & COO -
Pra Investors L.P.Kkr Pra I...,
-
Fund Holdings L.P.Kkr Fund ...,
-
Fund Holdings L.P.Kkr Fund ...,
-
David W Dockhorn,
Executive VP & CCO -
Linda Baddour,
Executive VP & CFO -
Pra Investors L.P.Kkr Pra I...,
-
Group Ltd Kkr Group Holding...,
-
Fund Holdings L.P.Kkr Fund ...,